Aptamers Market Size & Industry Outlook
The global aptamers market size reached US$ 189.99 Million in 2023 with a rise of US$ 221.53 Million in 2024 and is expected to reach US$ 972.38 Million by 2033, growing at a CAGR of 17.9% during the forecast period 2025-2033.
Aptamers, which work similarly to antibodies, are single-stranded DNA or RNA oligonucleotides that bind selectively to target molecules like proteins or tiny chemicals. Their excellent specificity, stability, and cost-effectiveness have led to their growing application in research, diagnostics, and treatments. In contrast to antibody-drug conjugate (ADC) technologies, which struggle with tissue penetration and drug conjugation control, aptamers provide accurate targeting and effective tissue access. Increasing R&D expenditures in pharmaceuticals and biotechnology, along with developments in screening and molecular design, are speeding up the production of aptamers because of their inexpensive cost of manufacturing, high yield, and adaptability, they are desirable substitutes for antibodies and are in high demand globally for use in therapeutic, diagnostic, and drug delivery applications.
Key Highlights
- North America is dominating the global aptamers market with the largest revenue share of a 48.5% in 2024
- The Asia Pacific region is the fastest-growing region in the global aptamers market, with a CAGR of 7.7% in 2024
- The nucleic acid aptamer segment from type is dominating the aptamers market with a 60.3% share in 2024
- The oncology segment from therapeutic area is dominating the aptamers market with a 41.3% share in 2024
- Top companies in the aptamers market include SomaLogic Operating Co., Inc., AM Biotechnologies, LLC, Aptagen, LLC, Base Pair Biotechnologies, Aptamer Innovations, Aptahem AB., NOVAPTECH, Aptamer Group, Aptamer Sciences, Inc., and Creative Biogene, among others.
Market Dynamics
Drivers: Rapid growth in diagnostic applications are accelerating the growth of the aptamers market
The aptamer market's growth has been driven by the developments in diagnostic applications. In disease diagnostics, aptamers provide ultra-sensitive detection due to their high specificity and affinity for a variety of targets. They are perfect substitutes for antibodies because to their stability, affordability, and ease of modification. Their commercial potential has increased due to growing usage in early illness detection systems, biosensors, and point-of-care diagnostics. Aptamers are used to facilitate non-invasive and precise testing in the diagnosis of infectious, neurological, and cancer diseases.
Furthermore, technology advancements like lateral flow assays, microfluidic sensors, and aptamer-based ELISA are accelerating the development of fast diagnostics. Global demand for aptamer-based diagnostic solutions is being driven by growing partnerships between biotech companies and diagnostic developers, which further improve validation and market expansion. For instance, in May 2025, Aptamer Group plc successfully advanced its Optimer-based Alzheimer’s disease test by adapting it into an ELISA format, widely used in hospital laboratories, and established a royalty agreement to support future commercialization and diagnostic market expansion.
Restraints: Low market acceptance as compared to antibodies is hampering the growth of the aptamers market
Aptamers' poor affinity is one of their main disadvantages. Aptamer market expansion has been hindered by low market acceptance in comparison to antibodies. Despite their cost-effectiveness, stability, and specificity, aptamers have had difficulty gaining acceptance in the scientific and medical worlds. Due to the limited binding contacts in their oligonucleotide structure, they have a decreased affinity for several targets. They lost some of their potency in biological systems due to nuclease breakdown and quick removal by liver, spleen, or renal filtration.
Additionally, the lack of regulatory permissions and validation also made researchers reluctant to replace well-established antibody-based methods. Aptamers can target a variety of compounds, but their uneven affinity and biological instability prevented them from being widely used.
For more details on this report, see Request for Sample
Aptamers Market, Segmentation Analysis
The global aptamers market is segmented based on type, therapeutic area, end users and region
By Type: The nucleic acid aptamer segment from type is dominating the aptamers market with a 60.3% share in 2024
The market for aptamers was led by the nucleic acid aptamer sector because of its exceptional stability and adaptability in a range of medicinal and diagnostic applications. These aptamers, which were made of DNA, RNA, or XNA, showed excellent binding affinity and selectivity for a variety of targets, such as cells, proteins, and tiny molecules. Their ease of synthesis, modification, and low-cost replication facilitated their commercial and scientific applications. They outperformed their protein-based counterparts in terms of reusability and thermal stability.
Moreover, the creation of high-performance nucleic acid aptamers was sped up by developments in next-generation sequencing and nucleic acid aptamer technology. For instance, in May 2025, Ajinomoto Co., Inc. and RIBOMIC Inc. successfully achieved a breakthrough in their joint research by extending the half-life of nucleic acid aptamers through conjugation with the Fc region of immunoglobulins using AJICAP technology, significantly improving pharmacokinetic control and enhancing the therapeutic potential of aptamer-based drugs.
By Therapeutic Area: The oncology segment from therapeutic area is dominating the aptamers market with a 41.3% share in 2024
Aptamers' great promise for targeted cancer therapy and diagnosis led the oncology segment to dominate the market. The widespread use of aptamers allowed for the precise identification of tumor-specific biomarkers, facilitating early cancer detection and efficient treatment administration. Their capacity to attach to cancer cells specifically reduced side effects in comparison to traditional treatments.
Moreover, their therapeutic value was increased by expanding research on aptamer-drug conjugates and cancer treatments based on nanoparticles. The development of aptamer-based medications for solid tumors and hematologic malignancies has drawn more attention from pharmaceutical corporations. For instance, in March 2024, Aptamer Sciences Inc. filed an IND application with the Korean Ministry of Food and Drug Safety for AST-201, its first aptamer-drug conjugate targeting the GPC3 protein in liver cancer. The candidate combined gemcitabine with a selective aptamer, offering a promising targeted therapy for advanced tumors.
Aptamers Market, Geographical Analysis
North America is dominating the global aptamers market with a 48.5% in 2024
North America dominated the aptamers market because of its extensive use of molecular diagnostics, robust R&D investments, and sophisticated healthcare infrastructure. The area led the market due to its emphasis on precision medicine, the existence of important biotech companies, a supportive regulatory environment, and the growing use of aptamer-based diagnostics and treatments.
In the USA, aptamer market growth was driven by expanding R&D investments, strong funding support for biotech innovation, and advancements in diagnostic and therapeutic applications. Owing to factors like funding. For instance, in June 2024, U.S.-based Aptatek BioSciences, Inc. completed a funding round led by Canterbury Scientific, LDT, and the National PKU Alliance following the successful clinical evaluation of its PheCheck aptamer-based in-home monitoring platform, aimed at advancing clinical studies for innovative phenylketonuria (PKU) patient monitoring solutions.
Europe is the second region after North America which is expected to dominate the global aptamers market with a 34.5% in 2024
In Europe, the aptamer market grew rapidly due to strong research funding, expanding biotech infrastructure, and rising adoption of molecular diagnostics. Favorable regulatory frameworks, continuous innovation in therapeutic and diagnostic applications, and increasing collaborations between research institutes and pharmaceutical companies further accelerated market expansion and commercialization across the region.
Moreover, European Union government funding to the research institution and universities for research and development further boosts market growth. For instance, in October 2023,Palacký University Olomouc got nearly €6 million in EU Horizon funding, and the 2D-BioPAD project developed a fast, reliable, and digitally enabled point-of-care diagnostic system using 2D materials and aptamers for early, multi-biomarker detection of Alzheimer’s disease.
The Asia Pacific region is the fastest-growing region in the global aptamers market, with a CAGR of 7.7% in 2024
The growing demand for targeted medicines, biotechnology breakthroughs, and higher R&D expenditures all contributed to the Asia-Pacific aptamers market's rapid expansion. The use of aptamer-based diagnostics and treatments in nations like China, Japan, India, and South Korea, as well as rising healthcare costs and encouraging government policies, all contributed to the market's expansion.
Japan’s aptamer market is growing rapidly, driven by robust research and development, increasing clinical trials, and strong academic-industry collaborations. Government support for biomedical innovation and advances in nucleic acid therapeutics is accelerating the translation of aptamer technologies.
Owing to factors like clinical trials, for instance, in October 2025, CAGE Bio initiated a randomized, double-blind, vehicle-controlled clinical trial to evaluate CGB-600, a novel topical DNA aptamer therapy for vitiligo. The investigational active pharmaceutical ingredient, licensed from TAGCyx Biotechnologies Inc., Japan, was designed to selectively bind interferon gamma and modulate autoimmune activity, causing melanocyte destruction.
Aptamers Market Competitive Landscape
Top companies in the aptamers market include SomaLogic Operating Co., Inc., AM Biotechnologies, LLC, Aptagen, LLC, Base Pair Biotechnologies, Aptamer Innovations, Aptahem AB. , NOVAPTECH, Aptamer Group, Aptamer Sciences, Inc., and Creative Biogene, among others.
SomaLogic Operating Co., Inc.: SomaLogic Operating Co., Inc. is a biotechnology company specializing in proteomics through its proprietary SomaScan platform, which uses aptamer-based technology to measure thousands of proteins simultaneously with high specificity and sensitivity. These synthetic DNA aptamers bind target proteins precisely, enabling powerful applications in biomarker discovery, diagnostics, and personalized medicine to advance healthcare and life sciences research.
Key Developments:
- In February 2025, a groundbreaking biotech collaboration between Naples and Tokyo led to the creation of Ophyx, a joint venture between BIOVIIIx and TAGCyx Biotechnologies. The partnership combined their ophthalmology pipelines to advance novel aptamer-based therapies, including a first-in-class DNA aptamer targeting interferon gamma for fast, effective treatment of eye diseases.
- In January 2024, SBI Pharmaceuticals and TAGCyx Biotechnologies advanced their joint research on innovative cancer treatments. The collaboration successfully completed screening and initial studies of cancer cell–specific DNA aptamers and moved to the next phase to validate and confirm their anti-cancer efficacy, marking significant progress in aptamer-based oncology research.
Market Scope
| Metrics | Details | |
| CAGR | 17.9% | |
| Market Size Available for Years | 2022-2033 | |
| Estimation Forecast Period | 2025-2033 | |
| Revenue Units | Value (US$ Mn) | |
| Segments Covered | By Type | Nucleic Acid Aptamer, Peptide Aptamer |
| By Therapeutic Area | Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders and Others | |
| By End Users | Pharmaceutical Companies, Academic and Research centers, Contract Research Organization and Others | |
| Regions Covered | North America, Europe, Asia-Pacific, South America and the Middle East & Africa | |
The global aptamers market report delivers a detailed analysis with 62 key tables, more than 54 visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.
Suggestions for Related Report
For more biotechnology-related reports, please click here
